Physician profile
Tamara Sobel
NPI 1194714857
$5,947.36
in general payments reported to CMS, 2019-2025
33 companies · $917 in 2025
The $917 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $310 · 2020: $263 · 2021: $581 · 2022: $927 · 2023: $1,574 · 2024: $1,375 · 2025: $917.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,866.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,866.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $922.39 | 2021-2025 | Ubrelvy, Vraylar, Synthroid |
| Lilly USA, LLC | $729.48 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $720.16 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Amgen INC. | $694.65 | 2019-2025 | Repatha, Otezla, Evenity |
| Pfizer INC. | $420.74 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $409.84 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $295.40 | 2021-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $260.79 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $157.91 | 2019-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $112.19 | 2021-2023 | Trintellix |
| Biohaven Pharmaceutical Holding Company Ltd. | $111.04 | 2022 | |
| Sumitomo Pharma America, INC. | $108.55 | 2023-2024 | Gemtesa |
| Daiichi Sankyo INC. | $107.25 | 2021-2024 | Injectafer |
| Idorsia Pharmaceuticals US INC | $78.78 | 2022-2023 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $78.74 | 2019-2025 | Zoryve |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $78.04 | 2021-2022 | |
| Eisai INC. | $76.88 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $73.92 | 2023-2025 | Capvaxive, Dificid, Gardasil 9 |
| Exact Sciences Corporation | $62.73 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $60.29 | 2019-2025 | Veozah |
| Esperion Therapeutics, INC. | $57.05 | 2023-2024 | Nexletol |
| E.R. Squibb & Sons, L.L.C. | $47.59 | 2023-2025 | Eliquis |
| Boston Scientific Corporation | $47.19 | 2023-2024 | Wavewriter Alpha Prime 16 |
| Allergan, INC. | $45.25 | 2020 | |
| Cleerly, INC. | $34.88 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Genzyme Corporation | $29.20 | 2022-2024 | |
| Bausch Health US, LLC | $23.58 | 2022 | |
| Kaleo, INC. | $21.62 | 2021 | |
| Philips North America LLC | $20.98 | 2024 | (Ck6) Holter |
| Abbott Laboratories | $17.43 | 2025 | Freestyle Libre 3 |
| Biohaven Pharmaceuticals, INC. | $17.18 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.99 | 2019 | |
| Sanofi Pasteur INC. | $12.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamara Sobel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.